"Targeting the Philippines" Samjin Pharmaceutical Secures Export Approval for Antiplatelet Drug Pleris Tablet

[Financial News] Samjin Pharmaceutical announced on the 13th that it has completed registration for export approval of its antiplatelet drug, Pleris Tablet, to the Philippines.
Pleris Tablet contains clopidogrel bisulfate and is prescribed as a monotherapy or in combination therapy for the treatment of cardiovascular, cerebrovascular, and peripheral arterial diseases. It is supplied to most major general hospitals in Korea and can also be used for patients undergoing drug-eluting stent (DES) procedures.
In addition to Pleris Tablet, Samjin Pharmaceutical is pursuing further export discussions for its newly launched anticoagulant Elxaban Tablet and anticancer drug Petra Tablet to diversify its product portfolio in the Philippine market. Elxaban Tablet received export approval in Azerbaijan earlier this year and has begun overseas shipments, marking an active push into international markets.
Kim Sang-jin, CEO of Samjin Pharmaceutical, stated, "Using our entry into the Philippines as a stepping stone, we will continue to expand the global export volume of our key pharmaceuticals," and added, "We will accelerate diversification of our overseas market entry by expanding our global network."
kaya@fnnews.com Choi Hye-rim Reporter